Introduction

The pharmaceutical industry is undergoing a significant transformation, driven by emerging technologies such as generative AI. This shift is enabling companies to unlock new opportunities, drive business success, and improve patient outcomes. A key aspect of this transformation is the ability to ask questions of data and have an interactive dialogue through generative AI, leading to innovation and the discovery of new ideas.

As Patrick Leyden, Director of Medical Affairs, Merck noted, "Innovation is what drives everything we do." This emphasis on innovation is crucial, as it allows companies to stay ahead of the curve and address the complex challenges facing the industry. However, innovation does not occur in a vacuum; it requires collaboration and a deep understanding of stakeholders' needs. Innovators must be bridge builders, helping people unlock their inherent creative potential and apply it to drive business success.

The integration of generative AI into existing processes is not without its challenges. Companies must be mindful of the need for effective communication and change management.

As Patrick Leyden observed,

"We thought our users would be ready for generative AI, but there's a large portion that weren't."

This highlights the importance of educating users about the capabilities and limitations of generative AI, including issues such as hallucination and confabulation.

To overcome these challenges, companies must prioritize communication and stakeholder engagement. As Patrick Leyden emphasized, "You can't talk enough" when it comes to introducing new technologies and processes. This includes providing clear explanations of what to expect and what not to expect from generative AI. By doing so, companies can ensure a smoother transition and maximize the benefits of these emerging technologies.

The future of generative AI in the pharmaceutical industry holds much promise. With a rich source of data being generated every hour, companies can explore new ways to analyze and visualize this data, driving insights and business success. The development of new large language models (LLMs) and AI technologies will continue to play a critical role in this process, but companies must prioritize strategic implications over technology for its own sake.

Key Takeaways:

1) Innovation is everyone's responsibility: As the speaker noted, "Everyone's an innovator" and should be encouraged to think big and reach out to people across the organization for ideas.

2) Collaboration is critical: Effective collaboration and communication are essential for driving business success and unlocking the potential of emerging technologies.

3) Change management is key: Companies must prioritize change management and communication when introducing new technologies and processes to ensure a smooth transition.

4) Generative AI requires education: Users must be educated about the capabilities and limitations of generative AI, including issues such as hallucination and confabulation.

5) Strategic implications should drive technology adoption: Companies should prioritize strategic implications over technology for its own sake, ensuring that new technologies align with business goals and objectives.

In conclusion, the pharmaceutical industry is undergoing a significant transformation, driven by emerging technologies such as generative AI. By prioritizing innovation, collaboration, and effective communication, companies can unlock new opportunities, drive business success, and improve patient outcomes. As the industry continues to evolve, it is essential to stay focused on strategic implications and prioritize the needs of stakeholders to ensure a successful and sustainable future.

"Medical and commercial will always have their separate roles. They will always be distinct in what they need to do. But there is no reason why you cannot have a single objective or single set of objectives what you're trying to accomplish,"

she explains.

The solution isn't about breaking down regulatory boundaries but aligning on common goals: "If you can align on the goal, it's not about the activities, it's not about the details of the road, it's about, are you trying to move in the same direction?"

Fostering Innovation Through the 90/10 Rule

To drive meaningful innovation, Gopal advocates for the "90/10 rule"—dedicating 90% of resources to essential activities while reserving 10% for creative exploration. She cites Google's approach of allowing employees to spend 20% of their time on creative projects, which led to innovations like Gmail and Google News.

However, she cautions that once an innovation shows promise, it requires full commitment: "They cannot be side projects once you choose to do something with them. If you decide you're going to do something coming out of that 10%, you have to be all in."

Implementing Change

Gopal outlines three key principles for implementing change:

1. Establish clear objectives and stay committed: "Pick a lane, get alignment and stay committed. You cannot have a different plan every six months."

2. Involve the right stakeholders early: "Get the right people around the table to say, okay, this is the idea. How are we going to make this happen? Not do I have permission to make it happen."

3. Proceed with determination: "You have to be enthusiastic when you're trying to make change. You have to believe and you have to commit. And you can't back down."

"Agility in pharma is not a contradiction. It is absolutely possible," Gopal concludes. "We are nimble when we need to be. How are we going to be nimble when we want to be?"

Key Takeaways

1) Shift from reactive to proactive change: "Imagine if you could turn that around and make it about, I see a need, I see an opportunity, and I want to change something. That's what creates agility."

2) Align medical and commercial objectives: "If you can align on the goal, it's not about the activities, it's not about the details of the road, it's about, are you trying to move in the same direction?"

3) Implement the 90/10 rule for innovation: "Let's dedicate 90% of our budget to things that need to happen... But let's leave 10% to think about things that we normally wouldn't think about."

4) Prepare concrete action plans, not just scenarios: "Being competitive means preparing for the pivot and having a plan in place that we can use immediately."

5) Learn from cross-industry approaches: "We need to be curious. I learn a lot from other industries. I don't think any industry is better or worse at moving with speed than pharma is."

"That's one of my big missions in my team – that people are getting a flavor and a taste of all of the different components of this ecosystem between the data, the digital and the operations,"

she says. "The more we are thinking of that holistically across this whole area, the better off we're going to be anticipating and seeing around corners."

Key Takeaways

1) Start with the customer experience: "A big part of it is really starting with our customer as the first point. How do we think about that person's experience? The things that are making them frustrated or standing in their way."

2) Embrace difficult change management: "Standing true to the notion that ultimately, on the other side of those tough decisions, there's a better future for the organization and maybe even for those individuals who are impacted."

3) Adapt to the digital-native clinician: "Our clinicians are changing and that inherently means that the way we engage with those clinicians has to evolve with them."

4) Maximize each interaction: "The number of times we get in front of these clinicians nowadays is going to be a lot fewer per time period, so each one of those conversations needs to be that much better and that much more planned out."

5) Foster cross-functional thinking: "I want the entire team to be thinking about data, thinking about digital and thinking about operations, regardless of which place you are in your function."

Text

For more insights on medical affairs, including latest articles, interviews and more – click here